论文部分内容阅读
目的:评价降纤酶对非ST段抬高心肌梗死的临床疗效及其对预后的影响。方法:选取2013年12月—2014年12月收治的非ST段抬高心肌梗死患者87例临床资料,按照治疗方法将其分为对照组(45例)和观察组(42例),对照组患者均给予常规治疗,观察组患者均给予在对照组常规治疗基础上,再给予注射用降纤酶治疗;评价两组患者治疗后的临床疗效用其对预后的影响。结果:观察组患者治疗后的总有效率为92.86%显著高于对照组为84.44%(P<0.05);治疗前,两组患者的血液流变学各项指标均经比较其差异其无统计学意义(P>0.05),治疗14 d后,观察组患者各项指标低于对照组(P<0.05)。结论:常规治疗与联用降纤酶对非ST段抬高心肌梗死患者具有较好的临床疗效,并且可显著提高其预后疗效。
Objective: To evaluate the clinical effect of defibrase on non-ST segment elevation myocardial infarction and its effect on prognosis. Methods: The clinical data of 87 patients with non-ST-elevation myocardial infarction who were admitted from December 2013 to December 2014 were divided into control group (n = 45) and observation group (n = 42) Patients were given conventional treatment, the observation group were given routine treatment in the control group on the basis of further treatment with defibrase injection; evaluation of two groups of patients after treatment with its prognostic impact. Results: The total effective rate after treatment in the observation group was 92.86%, which was significantly higher than that in the control group (84.44%, P <0.05). Before treatment, the indexes of hemorheology in both groups were not statistically different Significance (P> 0.05). After 14 days of treatment, the indexes in the observation group were lower than those in the control group (P <0.05). Conclusion: Both conventional and combined defibrase have better clinical efficacy in patients with non-ST elevation myocardial infarction and can significantly improve the prognosis.